KCT0009705
Completed
未知
Efficacy and safety evaluation study of Oryeongsan for stage I primary hypertension: Multicenter randomized, double-blind, placebo-controlled, parallel design Investigator initiated exploratory clinical trials
Wonkwang University, Gwangju Medical Center0 sites24 target enrollmentTBD
ConditionsDiseases of the circulatory system
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diseases of the circulatory system
- Sponsor
- Wonkwang University, Gwangju Medical Center
- Enrollment
- 24
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Aged \= 19 years old
- •2\) Before Randomized, if either of the following applies
- •\- 140 mmHg \=MSSBP \< 160 mmHg
- •\- 90 mmHg \= MSDBP \< 100 mmHg
- •3\) Those who are not currently taking anti\-hypertensive medication and who have not taken medication for hypertension within the last 4 weeks
- •4\) Those who have the ability and willingness to voluntarily agree to take part in the clinical trial and participate in the test
Exclusion Criteria
- •1\) At screening and randomized, MSSBP \= 160 mmHg or MSDBP \= 100 mmHg
- •2\) At screening, SSBP difference is \= 20 mmHg and SDBP difference\= 10mmHg
- •3\) Known or suspected secondary hypertension(ex. aortic coarctation, hyperaldosteronism, renal artery stenosis, Cushing's syndrome, pheochromocytoma, polycystic kidney disease)
- •4\) Patients with orthostatic hypotension with symptoms
- •5\) Unregulated diabetes (Excluding patients who do not need diabetes medication during the study period)
- •6\) Patients with severe heart disease, ischemic heart disease within 6months, peripheral vascular disease, Percutaneous Transluminal Coronary Angiography (PTCA), Coronary Artery Bypass Graft (CABG)
- •7\) Patients with significant ventricular tachycardia, atrial fibrillation, atrial flutter or other significant arrhythmia
- •8\) Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, immunologically significant aortic or mitral stenosis
- •9\) Subject with severe cerebrovascular disease (infarct, hemorrage) ithin recent 6 months.
- •10\) known severe or malignant retinopathy(retinal hemorrhage, visual disturbance, Retinal microaneurysms and so on within 6 months)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Efficacy and safety of solithromycin in patients with gonorrhea.gonorrhoeaTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2014-004040-36-Outside-EU/EEACempra Pharmaceuticals, Inc.300
Completed
Phase 4
ior EPOCIM ® in the management of anemia of the preterm infant.Phase IV.Anemia of newborn pretermRPCEC00000149Center of Molecular Immunology(CIM)121
Completed
Not Applicable
The effectiveness and safety of Hyeonggaeyeongyo-tang for chronic rhinitis according to pattern identification in Korean medicineKCT0001544Kyung Hee University40
Completed
Not Applicable
Evaluation of safety and effectiveness of the Osseofix Spinal Fracture Reduction System in treating spinal compression fracturesAcute vertebral compression fractures between levels T6 and L5Musculoskeletal DiseasesOther disorders of bone density and structureISRCTN26909676Alphatec Spine (UK)150
Recruiting
Not Applicable
Preliminary study on efficacy and safety of Kyung-Ok-Ko on cancer fatigue in lung cancer patients during cancer treatmentNeoplasmsKCT0003666Kyung Hee University Oriental Medical Center50